Literature DB >> 21561891

The immunophenotype of osteoclasts and macrophage polykaryons.

F Maggiani1, R Forsyth, P C W Hogendoorn, T Krenacs, N A Athanasou.   

Abstract

AIM: Osteoclasts are multinucleated cells which are specialised to carry out lacunar bone resorption. Osteoclasts form part of the mononuclear phagocyte system, and immunophenotypic criteria for distinction from macrophage polykaryons include expression of CD51 (vitronectin receptor) and absence of HLA-DR and CD14.
METHODS: The expression of CD14, CD163, HLA-DR and CD51 in formalin-fixed paraffin-embedded sections of normal bone and neoplastic and non-neoplastic lesions of bone and soft tissue known to contain osteoclasts and macrophage polykaryons respectively was assessed immunohistochemically; the immunophenotype of osteoclast-like giant cells in a wide range of giant cell-containing bone lesions was similarly assessed.
RESULTS: Both osteoclasts and macrophage polykaryons were found to express CD51. Macrophage polykaryons, but not osteoclasts, expressed CD14 and HLA-DR. CD51+/CD14-/HLA-DR-/CD163- giant cells were noted in all giant-cell lesions of bone, including giant cell tumour of bone, aneurysmal bone cyst, non-ossifying fibroma, chondroblastoma, telangiectatic osteosarcoma, chondromyxoid fibroma, Langerhans cell histiocytosis and brown tumour.
CONCLUSION: Our findings indicate that CD51 expression alone is not sufficient for immunocytochemical identification of osteoclasts, which do not express the macrophage-associated antigens CD14 and HLA-DR. Giant cells in most giant cell-rich lesions of bone have an osteoclast phenotype, suggesting that they are formed from mononuclear phagocyte osteoclast precursors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561891     DOI: 10.1136/jcp.2011.090852

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

Review 1.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

2.  Chondroclasts are mature osteoclasts which are capable of cartilage matrix resorption.

Authors:  H J Knowles; L Moskovsky; M S Thompson; J Grunhen; X Cheng; T G Kashima; N A Athanasou
Journal:  Virchows Arch       Date:  2012-07-11       Impact factor: 4.064

3.  Histological and clinical characteristics of malignant giant cell tumor of bone.

Authors:  Lihua Gong; Weifeng Liu; Xiaoqi Sun; Constantin Sajdik; Xinxia Tian; Xiaohui Niu; Xiaoyuan Huang
Journal:  Virchows Arch       Date:  2012-02-17       Impact factor: 4.064

4.  H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.

Authors:  Lihua Gong; Marilyn M Bui; Wen Zhang; Xiaoqi Sun; Ming Zhang; Ding Yi
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

5.  Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis.

Authors:  Iván Prieto-Potin; Raquel Largo; Jorge A Roman-Blas; Gabriel Herrero-Beaumont; David A Walsh
Journal:  BMC Musculoskelet Disord       Date:  2015-08-27       Impact factor: 2.362

6.  The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Authors:  Laura Mercatali; Chiara Spadazzi; Giacomo Miserocchi; Chiara Liverani; Alessandro De Vita; Alberto Bongiovanni; Federica Recine; Dino Amadori; Toni Ibrahim
Journal:  Int J Mol Sci       Date:  2016-11-01       Impact factor: 5.923

7.  Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.

Authors:  Astrid Lipplaa; Judith R Kroep; Lizz van der Heijden; Paul C Jutte; Pancras C W Hogendoorn; Sander Dijkstra; Hans Gelderblom
Journal:  Oncologist       Date:  2019-04-30

8.  Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?

Authors:  Mate E Maros; Peter Balla; Tamas Micsik; Zoltan Sapi; Miklos Szendroi; Holger Wenz; Christoph Groden; Ramses G Forsyth; Piero Picci; Tibor Krenacs
Journal:  Pathol Oncol Res       Date:  2021-05-03       Impact factor: 3.201

9.  Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors.

Authors:  Andrew L Folpe; Kemal Kösemehmetoğlu; Abbas Agaimy; Michael Michal; Robert Stoehr; Fulvia Ferrazzi; Pavel Fabian; Michal Michal; Alessandro Franchi; Florian Haller
Journal:  Mod Pathol       Date:  2021-03-19       Impact factor: 7.842

10.  High Expression of CD200 and CD200R1 Distinguishes Stem and Progenitor Cell Populations within Mammary Repopulating Units.

Authors:  Gat Rauner; Tania Kudinov; Shlomit Gilad; Gil Hornung; Itamar Barash
Journal:  Stem Cell Reports       Date:  2018-06-21       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.